Chronic lymphocytic leukemia (CLL) is characterized by the accumulation of clonally derived mature CD5
B cells in the blood of CLL patients are clonally related to CD5
high CLL B cells. We investigate whether CD5 state switching was likely to occur continuously as a common event or as a rare event in CLL by tracking somatic BCR mutations in bulk CLL B cells and using them to reconstruct the phylogenetic relationships and evolutionary history of the CLL in four patients. Using statistical methods, we show that there is no parsimonious route from a single or low number of CD5 low switch events to the CD5 high population, but rather, large-scale and/or dynamic switching between these CD5 states is the most likely explanation. The overlapping BCR repertoires between CD5 high and CD5 low cells from CLL patient peripheral blood reveal that CLL exists in a continuum of CD5 expression. The major proportion of 
Chronic lymphocytic leukemia (CLL) is characterized by the accumulation of clonally derived mature CD5
þ CD19 þ CD23 þ CD20 þ B cells in the blood, bone marrow, and secondary lymphoid organs [1] . CD5 is a glycoprotein normally found on T cells and a subset of immunoglobulin M (IgM)-secreting B cells known as B1a cells [2] , as well as regulatory B cells [3] , but not on the majority of peripheral blood (PB) B cells in healthy adults. Although expanded B-cell populations in CLL patients typically have high CD5 expression, the cellular origin of CLL is still unknown. CD5 þ CLL B cells show similar gene expression patterns to the healthy CD5 þ B-1a B cells [4] , but differ significantly from these cells with regard to other surface markers, exhibiting features of either activation or anergy after antigenic interactions [5] . As a result, there is still ambiguity as to whether CD5 is a marker of activation rather than of B-cell subtype [6] . The fluidity between CD5 þ and CD5 -states in normal B cells is demonstrated in vitro by the induction of CD5 cell-surface expression in B2-B cells by stimuli such as anti-IgM antibodies and phorbol 12-myristate-13-acetate [7, 8] and by downregulation of CD5 in CD5 þ B-1a B cells by exposure to cytokines [9] .
CLL patients regularly harbor CD5 low B cells, but the relationship of these cells to the leukemic cell bulk is unknown. If CD5 low B cells formed part of the CLL clone, then this would have important implications for monitoring, treating, and understanding the biology of CLL. Because CD5 expression is commonly used as a marker for CLL, the presence of CD5 low tumor B-cell populations would suggest that the ''true'' tumor load in patients is underestimated. Moreover, the identification of a CD5 low subpopulation in CLL would have significant implications for the development of therapeutic anti-CD5 monoclonal antibodies for CLL [10] [11] [12] . Furthermore, the study of the cellular origin and molecular pathogenesis of CLL would benefit from a better understanding of the diversity of clonal B cells and the role of any CD5 low subpopulation [4] given that studies normally focus on the CD5 þ/high B-cell populations [13] . Here, we first demonstrate the heterogeneity of CD5 expression within CLL clones from individual patients and identify dynamic relationships between CLL cells with high and low CD5 expression. We then show for the first time that there exists a largescale dynamic relationship between CD5 high and CD5 low B-cell populations in CLL, a phenomenon with implications for disease biology and treatment.
Methods
Patient samples PB mononuclear cells (PBMCs) were isolated from 10 mL of whole blood from four healthy volunteers and four CLL patients using Ficoll gradients (GE Healthcare) for bulk-sequencing experiments.
Single-cell and bulk-cell flow sorting were performed using CD20-FITC, CD19-PE, CD5-APC, and IgG-V450 (BD Biosciences) and Aqua (for live-dead cell detection, Invitrogen) into 96-well plates from 1.5-1.9 Â 10 6 frozen PBMCs per individual. Total RNA was isolated using TRIzol (Invitrogen) and purified using the RNeasy Mini Kit (Qiagen) including on-column DNase digestion according to the manufacturer's instructions. Research was approved by the relevant institutional review boards and ethics committees (07/ MRE05/44). Patient information is listed in Supplementary Tables  E1-E3 (online only, available at www.exphem.org).
B-cell receptor (BCR) amplification and sequencing
Reverse transcriptase polymerase chain reactions were performed using FR1 primers as described previously [14] . MiSeq libraries were prepared using Illumina protocols and sequenced using 300-bp paired-end MiSeq (Illumina). MiSeq reads were filtered for base quality (median O32) using QUASR [15] and pairedend reads merged if they contained identical overlapping regions of O65 bp or otherwise discarded. Non-Ig sequences were removed and only reads with significant similarity to reference Ig heavy chain variable (IgHV) genes in the international ImMunoGeneTics information system (IMGT) database [16] by BLAST [17] were retained (!1 Â 10 À10 E-value). Primer sequences were trimmed from reads and sequences were retained for analysis only if both forward and reverse primer sequences were identified and sequence lengths were greater than 240 bp for MiSeq. Single-cell BCR sequencing was performed as described previously [14] , with the number of PCR cycles increased to 50 and the PCR product undergoing Sanger sequencing. Only wells with a single BCR Sanger sequencing signal present were used in downstream analyses.
Network assembly and analysis
The network generation algorithm and network properties were calculated as in Bashford-Rogers et al. [14] . Briefly, each vertex represents a unique sequence in which relative vertex size is proportional to the number of identical sequence reads. Edges were generated between vertices that differed by single-nucleotide, non-indel differences and clusters were collections of related, connected vertices. Phylogenetic analyses were performed by alignment using Mafft [18] and maximum parsimony tree fitting using Paup* [19] . 
The hypergeometric test was used to determine the probability of observing, between CD5 high and CD5 low samples, equal or greater BCR sequence overlap than what would be expected by chance.
To test whether the CD5 high and CD5 low CLL B-cell BCR populations had a tendency to co-cluster, the nucleotide distances between any two sequences within or between the CD5 high and CD5 low CLL B-cell BCR populations was determined. The ratio between the mean nucleotide distances within versus between the CD5 high and CD5 low CLL B-cell BCR populations was calculated. By calculating this ratio from representatively sized random samples of the data (bootstrapping), the p value that the CD5 high and CD5
low CLL B-cell BCR populations were distinctly clusters rather than random mixing was determined. Here we used 1000 bootstraps of the data to calculate the p value.
Results
Single-cell sequencing reveals that CLL B cells have heterogeneous CD5 surface expression We first sought to determine whether CD5 low B cells can form part of the CLL clone in patients and to describe their relationship to CD5 high cells from the same CLL. Flow cytometry and cell sorting were performed on PB from four CLL patients (white blood counts ranged from 69.1 Â 10 9 to 102.4 Â 10 9 /L) and four healthy agematched individuals (summarized in Supplementary Table  E1 , online only, available at www.exphem.org). In agreement with previous studies [1] , we found considerably higher proportions of CD5 high B cells in the PB of all four CLL patients studied (O96% of CD20 þ B cells) compared with healthy, age-matched controls (4.6-7.4%, p ! 0.005; Supplementary Fig. E1 and Supplementary  Table E4 , online only, available at www.exphem.org). We also identified in all patients detectable populations of B cells with no or low-level expression of surface CD5 (w1.5-3.2% of B cells).
To study these CD5 low B cells, we first determined the clonal BCR sequences present in total PB lymphocytes, which were dominated by the CLL lymphocytes, and used these to mine identical sequences for clonal CLL cells in flow-sorted CD5 high /CD5 low B-cell populations at the single-cell level. BCRs are generated during B-cell development by site-specific DNA recombination of V, (D), and J genes, with nontemplate additions and deletions between genes. Therefore, each B-cell clone expresses a unique BCR sequence and we have used BCR sequencing previously to identify B cells originating from the same clone [14] . Next-generation sequencing of BCRs from cDNA of total PB B-cell populations from three CLL patients (two untreated and one previously treated with chlorambucil/rituximab; Supplementary Tables E1 and E2 , online only, available at www.exphem.org) yielded between 112,722 and 222,801 BCR sequences (after filtering for Ig similarity, length, and primer sequences removal according to Bashford-Rogers et al. [14] ). Network analysis was applied to these PBMC bulk-cell sequencing datasets to identify CLL clusters representing groups of highly related BCR sequences [14] , with each CLL patient sample exhibiting enlarged clusters of related sequences (identical IgHV-D-J rearrangements and joining regions), representing O85% of all BCR sequences (Fig. 1A) . These enlarged clusters corresponded to the BCRs expressed by the expanded CLL clone, similar to previous studies [14] . The IgHV-J combinations for these clusters were defined as IGHV4-34-IGHJ6, IGHV4-61-IGHJ4, and IGHV3-48-IGHJ4 for CLL patients 1, 2, and 3 respectively (Fig. 1Bi) .
After determining the CLL BCR sequences in bulk PB samples, we confirmed the presence of CLL cells in both the CD5 high and CD5 low B-cell subsets using single-cell BCR sequencing. CD5 high and CD5 low single B cells were sorted into 96-well plates (gating strategies in Supplementary Figs low BCR sequences also matched to the CLL clone sequence (i.e., the sequence was identical to a BCR present in the bulk CLL clonal cluster; Fig. 1B ; Supplementary Table E5, online only, available at www. exphem.org). Only one BCR sequence was detected in each single cell/well in all cases. Because putative cooccupancy of the same well by both a CD5 low non-CLL Figure 1 . Comparative analysis of CD5 high and CD5 low B-cell populations in CLL patients and healthy individuals. (A) Bulk-cell total PBMC BCR sequencing networks for CLL patients 1-3 with corresponding maximum cluster sizes and IgHV-J gene usage. Samples yielded 112,722, 222,801, and 151,777 BCR sequences for CLL patients 1, 2, and 3, respectively (after filtering for Ig similarity, length, and primer sequences removal according to Bashford-Rogers et al. [14] ). Sequencing networks are presented such that each vertex represents a unique BCR sequence in which relative vertex size is proportional to the number of identical sequence reads. Edges were generated between vertices that differed by single-nucleotide, non-indel differences and clusters were collections of related, connected vertices. The largest cluster sizes (CLL clusters) and corresponding IgHV-J combinations are indicated above and below the networks, respectively. high and CD5 low B-cell populations between the two healthy individuals ( Fig. 2A and 2B) ; however, significant overlap was observed between the CD5 high and CD5 low B-cell populations in the CLL patient (Fig. 2C) . Indeed, BCR sequence network analysis showed that the expanded cluster in the total (unsorted) PBMCs (comprising 99.85% of total BCR sequences with the [IGHV3-7*02-IGHD3-10*02-IGHJ4*02] rearrangement, Fig. 2Ei ) corresponded to the same clones in the expanded clusters in both the CD5 high and CD5 low B-cell samples (comprising 92.27% and 68.8% of total BCR sequences, respectively, Fig. 2Eii ). Expanded clones were not observed in the healthy B-cell samples (Supplementary  Table E6 , online only, available at www.exphem.org). The subclonal CLL BCR frequencies were highly correlated between the CD5 high and CD5 low subsets (R 2 5 0.98143, Fig. 2C ), revealing similar population structures between the two CLL B-cell populations. This suggests that the B-cell population structure is shared between the CD5 high and CD5 low B-cell subsets in CLL, unlike the CD5 high and CD5 low B-cell subsets in healthy individuals that exhibit unique B-cell populations. We observed that this difference in repertoire in CLL is due to the leukemic clone, in which there are no significant differences in repertoire structure in either CD5 high or CD5 low subsets once CLL clonal BCRs were removed from the repertoires ( Supplementary Fig. E5 , online only, available at www.exphem.org).
BCR phylogenetics reveals co-evolution of the CD5 (Fig. 2D) . To understand whether CD5 state switching was likely to occur continuously (a common event, randomly distributed over a phylogeny of CD5 high and CD5 low BCR sequences) or as a rare event (at a single point in CLL evolution, distributed along single lineages of CD5 high or CD5 low BCR sequences), we determined phylogenetic pattern of the CD5 high and CD5 low BCR sequences and the probability that an overlap of unique BCR sequences between the CD5 low and CD5 high samples can happen by chance after a single CD5 state-switching event.
The accumulation of mutations during CLL clonal expansion leading to intraclonal diversification within the BCR allowed us to reconstruct the phylogenetic relationships. Maximum parsimony trees were fitted using the CLL BCR sequences (i.e., BCRs represented in the largest network cluster) from each of the sorted CD5 low and CD5 high B-cell subsets (Fig. 2Eiii) . The central BCR in both CD5 high and CD5 low phylogenetic trees were identical, and was the most frequently observed BCR in both samples (comprising 85.6% and 85.7% of total CLL BCRs respectively). The star-like structures of both trees suggest that the original CLL clones in both the CD5 high and CD5 low B-cell subsets emerged from a single common ancestor, represented by the same central BCR [20] . When fitting a maximum high to CD5 low (scenario A), unidirectional switch from CD5 high to CD5 low (scenario B), and bidirectional dynamics switching/alternating between states (scenario C). These processes can be either a rare event (occurring only from a single or low number of CLL B cells) or a common/continuous event (occurring from a large percentage of the CLL B-cell population). (E) Determining the dynamics of CD5 state-switching in CLL patient 4: BCR sequence networks for total PBMCs (Ei) and BCR sequence networks for separated CD5 high B cells (Eii, left) and CD5 low B cells (Eii, right). The dominant cluster sizes are indicated above each plot. (Eiii) Combined maximum parsimony phylogenetic tree of the CLL cluster generated using the combined CLL BCR sequences from the separated CD5 high and CD5 low B-cell populations from (Eii). The branch lengths are proportional to the number of base differences from the central BCR sequence ( high sequences do not subcluster significantly into distinct groups on the phylogenetic tree (p 5 0.509; Supplementary Fig. E6 , online only, available from www. exphem.org), suggesting that there is no parsimonious route to a single or low number of switch events followed by fixed BCR sequence lineages in CD5 high and CD5 low CLL. This study supports a hypothesis that CD5 state switching is likely to occur as a common event and continuous switching may occur, although not at an equal frequency as CD5 high / CD5 low ratios in CLL do not tend to 1. Decreased CD5 expression corresponds with the normal development of B cells to plasma cells [21] and it is possible that the CD5 low CLL population represents further differentiated CLL subclones.
Conclusions
Our study shows that CD5 high and CD5 low tumor B cells were present in all CLL patients studied and displayed very similar population structures as determined by the phylogeny of their BCR repertoires. The overlapping BCR repertoires between CD5 high and CD5 low cells from CLL blood cells show that the disease encompasses a continuum of CD5 expression levels. This indicates that the CD5 state of CLL cells is subject to changes in CD5 expression and the observed dominance of CD5 high cells represents an equilibrated flux rather than a fixed state. Indeed, if the CD5 low CLL B-cell population were hierarchically above (i.e., closer to or containing stem cells) the CD5 high population, then the CD5 low CLL B-cell population would be a more effective treatment target than CD5
high . Alternatively, if the CD5 low CLL B-cell population is hierarchically below the CD5 high CLL B-cell population (i.e., closer to differentiation and/or apoptosis), then understanding how CD5 expression can become downregulated may represent a therapeutic approach. Indeed, we show that decreased CD5 expression is associated with differences in CD81 and CD45 cell surface expression ( Supplementary  Fig. E7 , online only, available at www.exphem.org), which may reflect biological differences between these groups of CLL cells. Together, these data suggest that CD5 low B cells are an important component of CLL that may be able to propagate and act as a residual disease population, with implications for understanding CLL pathogenesis, minimal residual disease, and developing anti-CD5-directed therapies. Patients were selected for this study presented with a range of different prognostic factors and follow up information to ensure that the trends observed here could be generalized to multiple CLL subtypes. CLL 1, 2, and 3 exhibited 13q deletions, which are associated with good prognosis [1] , and CLL 4 showed no known genomic abnormalities. A further prognostic factor is the IgHV mutation status, where unmutated IgHV (displayed in CLL 1 and 4) has a significantly inferior prognosis to mutated IgHV (displayed in CLL 2 and 3). Supplementary Figure ter sizes (as a percentage of total reads) and (B) hierarchical clustering of IgHV-J gene usage similarities between CD5 high (red) and CD5 low (green) B-cell populations for two healthy individuals and CLL patient 4 (either for all reads in the sample, or all reads that were unrelated to the CLL clone, defined as O30 bp differences and/or O10 gaps within an alignment from the CLL clonal sequence). The CD5 high and CD5 low samples from patient 4 have increased clonality compared to healthy individuals ( Supplementary Fig. E5A ). However when the sequences related to the CLL clone are removed from the CD5 high and CD5 low samples (i.e., the nonleukemic counterpart of the repertoire), there is no significant difference in clonality of V-J gene usage frequencies. Both CD5 high and CD5 low samples from CLL patient 4, when excluding the CLL clone, cluster together with the healthy individuals.
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Supplementary Figure E6 . low and CD5 high sequences subcluster into distinct groups on the phylogenetic tree (where the null hypothesis is that they are randomly distributed on the phylogenetic tree), the distances were randomly sampled at the same proportions, and the histogram of distance ratios of within groups versus between groups was calculated for each iteration. The p value for which the observed data distance ratio was nonrandom is not significant (bootstrapped p 5 0.509), suggesting that the null hypothesis should be accepted and the sequences that generate the pairwise distances are randomly distributed on the tree (i.e., there is no parsimonious route to a single or low number of switch events). high and CD5 low BCR sequences from the sequencing data in Figure 2 . **** p value ! 10 À6 . Flow-cytometric fluorescence intensities of fluorophore-conjugated antibodies against a set of CLL-associated B-cell surface antigen (namely CD81, CD22, CD38, CD20, CD19, and CD45) were used to quantify cell-surface expression in the CLL clone. Notably, the mean of fluorescence (MFI) for the expression of both CD45 and CD81 by circulating CLL B cells was significantly lower for CD5 low B cells compared to CD5 high B cells (paired t-test p values of 0.011 and 0.00023, respectively; Supplementary  Fig. E7 ). CD45 is normally found on all leukocytes, where previous studies show CD45 plays a positive regulatory role during B-cell receptor signaling [13] . CD81 is usually expressed at high levels in normal germinal center B cells, and associated with mutated CLL. This is in agreement with our data, as the CD5 high CLL B cells are associated with a higher number of mutations within the CLL clone as well as higher CD81 levels.
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